Vernon Scott, MD
Family Medicine · Tuscaloosa, ALNPI 1992786958
Payments from drug & device makers
Across 156 payments — averaging $17.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$822
- Novo Nordisk$359
- Pfizer$328
- Astellas Pharma US Inc$186
- Boehringer Ingelheim$146
- Merck$102
- plus $714 from 18 others
What the payments were for
- Food & beverage$2,56196%
- Education$954%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 50 | $822 |
| Novo Nordisk | 22 | $359 |
| Pfizer | 18 | $328 |
| Astellas Pharma US Inc | 7 | $186 |
| Boehringer Ingelheim | 9 | $146 |
| Merck | 8 | $102 |
| Dexcom, Inc. | 4 | $84 |
| Novartis | 4 | $66 |
| Lilly USA, LLC | 4 | $61 |
| GSK | 4 | $59 |
| AbbVie(2 entities) | 3 | $53 |
| Exact Sciences | 3 | $52 |
| Sanofi Pasteur Inc. | 3 | $49 |
| Amarin Pharma, Inc. | 3 | $47 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $39 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Amgen(2 entities) | 2 | $35 |
| Johnson & Johnson | 2 | $32 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Hologic Sales And Service, LLC | 1 | $20 |
| AstraZeneca | 1 | $14 |
| Abbott | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Eisai Inc. | 1 | $13 |
How this compares
$2,656 in reported general payments places this provider in the 70th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 363 | $454,491 |
| OzempicSemaglutide | 160 | $262,761 |
| EliquisApixaban | 186 | $165,391 |
| JanuviaSitagliptin Phosphate | 119 | $119,344 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 280 | $90,385 |
| TrulicityDulaglutide | 50 | $83,080 |
| XareltoRivaroxaban | 60 | $67,851 |
| RybelsusSemaglutide | 30 | $57,056 |
| LinzessLinaclotide | 47 | $55,314 |
| MounjaroTirzepatide | 43 | $51,279 |
| TradjentaLinagliptin | 47 | $50,660 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $45,674 |
| EntrestoSacubitril/Valsartan | 34 | $35,936 |
| JanumetSitagliptin Phos/Metformin Hcl | 32 | $32,322 |
| MyrbetriqMirabegron | 43 | $30,360 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $146 | $520,009424 claims |
| Novo NordiskOzempic, Rybelsus | $359 | $319,817190 claims |
| PfizerEliquis, Abrysvo | $328 | $255,776466 claims |
| MerckJanuvia, Janumet, Janumet Xr | $102 | $166,799164 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $61 | $134,35993 claims |
| AbbVieLinzess, Vraylar | $53 | $83,40567 claims |
| GSKTrelegy Ellipta, Shingrix, Breo Ellipta, Incruse Ellipta | $59 | $78,422127 claims |
| Johnson & JohnsonXarelto | $32 | $67,85160 claims |
| NovartisEntresto | $66 | $35,93634 claims |
| Astellas Pharma US IncMyrbetriq | $186 | $30,36043 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $822 | $28,70814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Tuscaloosa
- Kelly HunterTuscaloosa$84K
- Ross SummerfordTuscaloosa$18K
- Craig BuettnerTuscaloosa$17K
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.